Sigma receptor ligands and methods of modulating cellular protein homeostasis using same
The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.
1. A method of treating neuropathic pain in a subject, the method comprising administering to the subject a compound of Formula (II):
R A —R B (II),
wherein:
R A is selected from the group consisting of:
X 4 is selected from the group consisting of OCH 3 , F, Cl, Br, and I; and
R B is selected from the group consisting of:
or a salt, solvate, or N-oxide thereof; and any combinations thereof.
2. The method of claim 1 , wherein the compound is selected from the group consisting of 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A); 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B); 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G); or a salt, solvate or N-oxide thereof, and any combinations thereof.
3. The method of claim 1 , wherein R A is
4. The method of claim 1 , wherein R A is
5. The method of claim 4 , wherein X 4 is selected from the group consisting of F, Cl, Br, and I.
6. The method of claim 4 , wherein X 4 is OCH 3 .
7. The method of claim 1 , wherein R A is
8. The method of claim 1 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-iodophenyl)guanidine (Compound A), or a salt, solvate or N-oxide thereof, and any combinations thereof.
9. The method of claim 1 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-methoxyphenyl)guanidine (Compound B), or a salt, solvate or N-oxide thereof, and any combinations thereof.
10. The method of claim 1 , wherein the compound is 1-(3-(4-fluorophenoxy)propyl)-3-(4-chlorophenyl)guanidine (Compound G), or a salt, solvate or N-oxide thereof, and any combinations thereof.
11. The method of claim 1 , wherein the compound is part of a pharmaceutical composition, which is formulated for at least one selected from the group consisting of sustained release, delayed release, and pulsatile release.
12. The method of claim 1 , wherein the compound is administered to the subject by at least one administration route selected from the group consisting of oral, parenteral, transdermal, transmucosal, intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical.
13. The method of claim 1 , wherein the compound is part of a pharmaceutical composition, which is a cream or lotion.
14. The method of claim 1 , wherein the compound is part of a pharmaceutical composition, which further comprises least one additional therapeutic agent.
15. The method of claim 1 , wherein the compound is part of a pharmaceutical composition, which is administered in the form of a transdermal patch.
16. The method of claim 2 , wherein the compound is part of a pharmaceutical composition, which is administered in the form of a transdermal patch.
17. The method of claim 1 , wherein the subject is a mammal.
18. The method of claim 17 , wherein the mammal is a human.